Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Merck ( MRK) is a global biopharmaceutical giant with a diversified portfolio that spans across oncology, vaccines, ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Teva Pharmaceutical ( NYSE: TEVA) and Shanghai Fosun Pharmaceutical announced a collaboration on Monday to develop TEV-56278, a new therapy aimed at treating various cancers through an anti-PD1-IL2 ...

The recent experience of Chinese biotech companies in developing their own drug candidates and inking deals with larger ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

DelveInsight’s Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ ...